TuHURA Biosciences, Inc./NV SEC filings HURA
TuHURA Biosciences, Inc./NV has 928 filings in SEC EDGAR's recent list, going back to Aug 17, 2010. Its latest annual report, Form ARS, was filed on Jul 9, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 16, 2026 (new debt). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| D | Filing | Nov 10, 2025 | — |
| EFFECT | Filing | Sep 26, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 25, 2025 | — |
| CORRESP | Letter to the SEC | Sep 24, 2025 | — |
| CORRESP | Letter to the SEC | Sep 18, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 28, 2025 | — |
| CORRESP | Letter to the SEC | Aug 25, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 20, 2025 | — |
| 425 | Filing | Jun 24, 2025 | — |
| D | Filing | Jun 13, 2025 | — |
| 425 | Filing | Jun 6, 2025 | — |
| 425 | Filing | Jun 3, 2025 | — |
| 425 | Filing | May 15, 2025 | — |
| EFFECT | Filing | May 14, 2025 | — |
| 425 | Filing | May 13, 2025 | — |
| CORRESP | Letter to the SEC | May 12, 2025 | — |
| 425 | Filing | May 7, 2025 | — |
| CORRESP | Letter to the SEC | May 6, 2025 | — |
| 425 | Filing | May 5, 2025 | — |
| 425 | Filing | Apr 28, 2025 | — |
| 425 | Filing | Apr 8, 2025 | — |
| 425 | Filing | Apr 1, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 20, 2025 | — |
| 425 | Filing | Dec 12, 2024 | — |
| EFFECT | Filing | Oct 15, 2024 | — |
| 425 | Filing | Oct 4, 2024 | — |
| NT 10-K | Filing | Sep 30, 2024 | Jun 30, 2024 |
| 425 | Filing | Sep 25, 2024 | — |
| 425 | Filing | Sep 24, 2024 | — |
| 425 | Filing | Sep 20, 2024 | — |
| 425 | Filing | Sep 19, 2024 | — |
| 425 | Filing | Sep 18, 2024 | — |
| 425 | Filing | Sep 11, 2024 | — |
| 425 | Filing | Sep 9, 2024 | — |
| 425 | Filing | Sep 3, 2024 | — |
| 425 | Filing | Aug 19, 2024 | — |
| SEC STAFF LETTER | Filing | Aug 13, 2024 | — |
| EFFECT | Filing | Aug 13, 2024 | — |
| CORRESP | Letter to the SEC | Aug 12, 2024 | — |
| CORRESP | Letter to the SEC | Aug 8, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 1, 2024 | — |
| CORRESP | Letter to the SEC | Jul 19, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 10, 2024 | — |
| 425 | Filing | Jul 8, 2024 | — |
| 425 | Filing | Jul 1, 2024 | — |
| CORRESP | Letter to the SEC | Jun 27, 2024 | — |
| 425 | Filing | Jun 13, 2024 | — |
| SEC STAFF LETTER | Filing | Jun 10, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 7, 2024 | — |
| 425 | Filing | Jun 3, 2024 | — |
| 425 | Filing | May 14, 2024 | — |
| 425 | Filing | Apr 25, 2024 | — |
| 425 | Filing | Apr 3, 2024 | — |
| RW | Filing | Mar 13, 2024 | — |
| EFFECT | Filing | Apr 1, 2021 | — |
| CORRESP | Letter to the SEC | Mar 30, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 30, 2021 | — |
| EFFECT | Filing | Nov 4, 2020 | — |
| CORRESP | Letter to the SEC | Nov 2, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 30, 2020 | — |
| D | Filing | Aug 28, 2020 | — |
| D | Filing | Aug 27, 2020 | — |
| 425 | Form 425 | Aug 18, 2020 | — |
| 425 | Current report | Aug 17, 2020 | — |
| 425 | Form 425 | Jul 28, 2020 | — |
| EFFECT | Filing | Jul 2, 2020 | — |
| CORRESP | Letter to the SEC | Jun 30, 2020 | — |
| 425 | Form 8-k | Jun 24, 2020 | — |
| UPLOAD | Letter from the SEC | Jun 23, 2020 | — |
| 425 | Form 8-k | Jun 10, 2020 | — |
| EFFECT | Filing | Nov 20, 2019 | — |
| EFFECT | Filing | Nov 20, 2019 | — |
| POS EX | Form pos ex | Aug 15, 2019 | — |
| EFFECT | Filing | Aug 14, 2019 | — |
| CORRESP | Letter to the SEC | Aug 9, 2019 | — |
| CORRESP | Letter to the SEC | Aug 9, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 6, 2019 | — |
| EFFECT | Filing | Jul 16, 2019 | — |
| CORRESP | Letter to the SEC | Jul 11, 2019 | — |
| UPLOAD | Letter from the SEC | Jul 2, 2019 | — |
| RW | Registration withdrawal request | Jun 27, 2019 | — |
| EFFECT | Filing | May 28, 2019 | — |
| CORRESP | Letter to the SEC | May 23, 2019 | — |
| CORRESP | Letter to the SEC | May 8, 2019 | — |
| UPLOAD | Letter from the SEC | Apr 24, 2019 | — |
| EFFECT | Filing | Feb 19, 2019 | — |
| CORRESP | Letter to the SEC | Feb 19, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 11, 2019 | — |
| EFFECT | Filing | Sep 27, 2016 | — |
| EFFECT | Filing | Sep 27, 2016 | — |
| CORRESP | Letter to the SEC | Sep 23, 2016 | — |
| UPLOAD | Letter from the SEC | Sep 23, 2016 | — |
| EFFECT | Filing | Sep 21, 2016 | — |
| CT ORDER | Filing | Sep 13, 2016 | — |
| CERTNAS | Auto-generated paper document | Jul 11, 2016 | — |
| 8-A12B | Form 8-a | Jul 8, 2016 | — |
| D | Filing | May 10, 2016 | — |
| EFFECT | Filing | Nov 30, 2015 | — |
| EFFECT | Filing | Jul 15, 2015 | — |
| CORRESP | Letter to the SEC | Jul 14, 2015 | — |
| CORRESP | Letter to the SEC | Jul 2, 2015 | — |
| CORRESP | Letter to the SEC | Jul 2, 2015 | — |
| CORRESP | Letter to the SEC | Jul 1, 2015 | — |
| CORRESP | Letter to the SEC | Jul 1, 2015 | — |
| CORRESP | Letter to the SEC | May 14, 2015 | — |
| CORRESP | Letter to the SEC | May 14, 2015 | — |
| CORRESP | Letter to the SEC | May 12, 2015 | — |
| CORRESP | Letter to the SEC | May 12, 2015 | — |
| UPLOAD | Letter from the SEC | Apr 14, 2015 | — |
| EFFECT | Filing | Mar 13, 2015 | — |
| SC TO-I/A | Amendment no. 2 to form sc to-i | Feb 10, 2015 | — |
| CORRESP | Letter to the SEC | Jan 23, 2015 | — |
| SC TO-I/A | Delmar pharmaceuticals, inc. form sc to-i/a | Jan 23, 2015 | — |
| UPLOAD | Letter from the SEC | Jan 16, 2015 | — |
| SC TO-I | Tender offer statement | Jan 8, 2015 | — |
| SC TO-I/A | Delmar pharmaceuticals, inc. sc to-i/a | Aug 12, 2014 | — |
| SC TO-I/A | Delmar pharmaceuticals, inc. sc to-i/a | Jul 29, 2014 | — |
| SC TO-I/A | Delmar pharmaceuticals, inc. form schedule to-i/a | Jul 10, 2014 | — |
| CORRESP | Letter to the SEC | Jun 26, 2014 | — |
| SC TO-I/A | Delmar pharmaceuticals, inc. form schedule to-i/a | Jun 26, 2014 | — |
| UPLOAD | Letter from the SEC | Jun 18, 2014 | — |
| SC TO-I | Delmar pharmaceuticals, inc. schedule to | Jun 9, 2014 | — |
| EFFECT | Filing | Apr 29, 2014 | — |
| EFFECT | Filing | Jun 28, 2013 | — |
| UPLOAD | Letter from the SEC | Apr 8, 2013 | — |
| CT ORDER | Filing | Apr 8, 2013 | — |
| CORRESP | Letter to the SEC | Mar 14, 2013 | — |
| D/A | Filing | Mar 7, 2013 | — |
| UPLOAD | Letter from the SEC | Feb 27, 2013 | — |
| D/A | Filing | Feb 14, 2013 | — |
| D/A | Filing | Feb 8, 2013 | — |
| D | Filing | Feb 8, 2013 | — |
| SC 14F1 | Delmar pharmaceuticals, inc. form sc 14f1 | Jan 30, 2013 | — |
| NT 10-K | Form 12b-25 of berry onlly | Sep 28, 2012 | Jun 30, 2012 |
| 8-A12G | Form 8-a of berry only inc | Sep 14, 2012 | — |
| NT 10-Q | Filing | May 16, 2012 | Mar 31, 2012 |
| EFFECT | Filing | Dec 22, 2010 | — |
| CORRESP | Letter to the SEC | Dec 20, 2010 | — |
| CORRESP | Letter to the SEC | Dec 9, 2010 | — |
| CORRESP | Letter to the SEC | Dec 2, 2010 | — |
| UPLOAD | Letter from the SEC | Nov 22, 2010 | — |
| CORRESP | Letter to the SEC | Nov 12, 2010 | — |
| UPLOAD | Letter from the SEC | Oct 27, 2010 | — |
| CORRESP | Letter to the SEC | Oct 15, 2010 | — |
| UPLOAD | Letter from the SEC | Oct 6, 2010 | — |
| CORRESP | Letter to the SEC | Sep 23, 2010 | — |
| UPLOAD | Letter from the SEC | Sep 10, 2010 | — |
Showing 147 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HURA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Tampa, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1498382
- Former names
- Kintara Therapeutics, Inc. (until Oct 22, 2024); DelMar Pharmaceuticals, Inc. (until Aug 18, 2020); Berry Only Inc. (until Jan 18, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.